替格瑞洛联合增强型体外反搏对不稳定型心绞痛患者心功能和生活质量的影响

Effect of Tigrelor combined with enhanced external counterpulsation on cardiac function and quality of life in patients with unstable angina pectoris

下载PDF

导出

摘要目的:探讨替格瑞洛联合增强型体外反搏对不稳定型心绞痛患者心功能和生活质量的影响。方法:将本院2021年5月至2022年7月收治的100例不稳定型心绞痛患者数字表法随机分为对照组和观察组,每组50例。对照组患者予替格瑞洛治疗,观察组患者在对照组基础上,同时用增强型体外反搏,治疗2个月后,心电图检测两组患者治疗前后心肌缺血次数和缺血时间,超声诊断仪检测两组患者治疗前后左室射血分数(LVEF)、左室收缩末期内径(LVESD)和左室舒张末期内径(LVEDD),以焦虑自评量表(SAS)和抑郁自评量表(SDS)评估患者精神状态,以西雅图心绞痛量表(SAQ)评估患者生活质量,统计不良反应情况。结果:治疗后,对照组和观察组患者心肌缺血次数[(3.06±0.31),(2.04±0.20)次]和缺血时间[(6.34±2.04),(4.18±1.32)min]均较治疗前降低[(4.58±1.01),(4.30±1.11)次]、[(10.48±2.51),(10.76±2.23)min],且观察组低于对照组(P<0.05)。治疗后,对照组和观察组患者LVEF[(45.68±5.22),(48.14±5.22)%]均较治疗前[(39.84±4.72),(39.98±4.20)%]升高,且观察组高于对照组(P<0.05);治疗后,对照组和观察组患者LVESD[(40.74±3.14),(37.64±3.90)mm]和LVEDD[(48.66±4.58),(44.72±4.10)mm]均较治疗前[(46.80±3.41),(47.34±3.54)mm],[(53.84±5.57),(54.16±5.34)mm]降低,观察组低于对照组(P<0.05)。治疗后,对照组和观察组患者SDS[(42.12±4.61),(36.48±4.70)分]和SAS[(40.58±4.04),(35.26±4.62)分]均较治疗前[(55.94±5.10),(55.78±5.03)分],[(52.78±4.23),(52.88±4.13)分]降低,且观察组低于对照组(P<0.05)。治疗后,对照组和观察组患者SAQ评分[(86.30±9.05),(95.24±9.86)分]高于治疗前[(62.88±7.42),(63.92±7.47)分],且观察组高于对照组(P<0.05);两组患者治疗过程中均未出现不良反应。结论:替格瑞洛联合增强型体外反搏对可有效减少不稳定型心绞痛患者心肌缺血次数,缩短缺血时间,改善心功能和精神状态,提高患者生活质量。 Objective:To investigate the effects of Tigrelor combined with enhanced external counterpulsation on cardiac function and quality of life in patients with unstable angina pectoris.Methods:A total of 100 patients with unstable angina treated in our hospital from May 2021 to July 2022 were selected and divided into control group and observation group according to random number table method,with 50 cases in each group.The control group was treated with ticagrelor,the observation group was treated with enhanced external counterpulsation on the basis of control group.After 2 month of treatment,the number and time of myocardial ischemia before and after treatment were measured by electrocardiogram,left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD)and left ventricular end-diastolic diameter(LVEDD),the self-rating anxiety scale(SAS)and self-rating depression scale(SDS)assessed patients’negative emotions.Seattle angina question-naire(SAQ)was used to assess patients’quality of life and observed the occurrence of adverse reactions in the two groups during treatment.Results:After treatment,number of of patients with myocardial ischemia[(3.06±0.31),(2.04±0.20)]and ischemic time[(6.34±2.04),(4.18±1.32)min]were reduced than that before treatment in both groups[(4.58±1.01),(4.30±1.11)],[(10.48±2.51),(10.76±2.23m in)],and the observation group was lower than the control group(P<0.05).After treatment,LVEF in control group and observation group[(45.68±5.22),(48.14±5.22)%]was higher than that before treatment[(39.84±4.72),(39.98±4.20)%],and observation group was higher than control group(P<0.05).After treatment,the LVESD[(40.74±3.14),(37.64±3.90)mm]and LVEDD[(48.66±4.58),(44.72±4.10)mm]were decreased than that before treatment[(46.80±3.41),(47.34±3.54)mm],[(53.84±5.57),(54.16±5.34)mm]which was lower in the observation group than in the control group(P<0.05).After treatment,the SDS[(42.12±4.61),(36.48±4.70)points]and SAS[(40.58±4.04),(35.26±4.62)points]were decreased than that before treatment[(55.94±5.10),(55.78±5.03)points]and[(52.78±4.23),(52.88±4.13)points],and the observation group was lower than the control group(P<0.05).After treatment,the SAQ scores of control group and observation group[(86.30±9.05),(95.24±9.86)]were higher than those before treatment[(62.88±7.42),(63.92±7.47)],and the observation group was higher than the control group(P<0.05).There were no adverse reactions during treatment in both groups.Conclusion:Ticagrelor combined with enhanced external counterpulsation can effectively reduce the number of myocardial ischemia in patients with unstable angina pectoris,shorten the ischemic time,improve cardiac function,relieve anxiety and depression,and improve the quality of life of patients.

作者张丽李华伟徐静宜 ZHANG Li;LI Hua-wei;XU Jing-yi(Department of Fourth Cardiology,the Third Hospital of Xingtai,Xingtai 054000,China)

机构地区邢台市第三医院心内四科

出处《中国药物应用与监测》 CAS 2023年第4期250-254,共5页 Chinese Journal of Drug Application and Monitoring

基金邢台市重点研发计划自筹项目(2022ZC117)。

关键词不稳定型心绞痛心功能生活质量替格瑞洛增强型体外反搏 Unstable angina pectoris Cardiac function Quality of life Tigrillo Enhanced external counterpulsation

分类号 R541 [医药卫生—心血管疾病]